Results & Publications

BARI 2D Publications

  1. Sobel BE, Frye R, Detre KM. Burgeoning dilemmas in the management of diabetes and cardiovascular disease: Rationale for the BARI 2D trial. Circulation 2003;107(4):636-642. PMID: 12566379.
  2. Iskandrian AE, Heo J, Mehta D, Tauxe EL, Yester M, Hall MB, MacGregor JM. Gated SPECT perfusion imaging for the simultaneous assessment of myocardial perfusion and ventricular function in BARI 2D: An initial report from the Nuclear Core Laboratory. Journal of Nuclear Cardiology 2006;13:83-90. PMID: 16464721.
  3. Detre KM, Frye RL, Genuth S, guest editors. A symposium: treatment of coronary artery disease and type 2 diabetes: the rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. American Journal of Cardiology 2006;97(suppl 12A):1G-65G.
  4. Steiner G for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial Investigators. Statement of the problem. American Journal of Cardiology2006;97(suppl 12A):3G-8G. PMID: 16813733.
  5. Brooks MM, Frye RL, Genuth S, Detre KM, Nesto R, Sobel BE, Kelsey SF, Orchard TJ for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial Investigators. Hypotheses, design and methods for the Bypass Angioplasty Revascularization Investigation 2 (BARI 2D) trial. American Journal of Cardiology2006;97(suppl 12A):9G-19G. PMID: 16813734.
  6. Magee MF, Isley WL for the BARI 2D Trial Investigators. Rationale, Design, and Methods for Glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. American Journal of Cardiology 2006;97(suppl 12A):20G-30G. PMID: 16813735.
  7. Barsness GW, Gersh BJ, Brooks MM, and Frye RL for the BARI 2D Trial Investigators. Rationale for the Revascularization Arm for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. American Journal of Cardiology 2006;97(suppl 12A):31G-40G. PMID: 16813736.
  8. Albu J, Gottlieb SH, August P, Nesto RW, and Orchard TJ for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial Investigators. Modifications of coronary risk factors. American Journal of Cardiology 2006;97(suppl 12A):41G-52G. PMID: 16813737. PMCID: PMC2670550.
  9. Sobel BE for the BARI 2D Trial Investigators. Ancillary studies in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial: Synergies and Opportunities.American Journal of Cardiology 2006;97(suppl 12A):53G-58G. PMID: 16813738.
  10. Hlatky MA, Melsop KA, and Boothroyd DB for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial Investigators. Economic evaluation of alternative strategies to treat patients with diabetes mellitus and coronary artery disease. American Journal of Cardiology 2006;97(suppl 12A):59G-65G. PMID: 16813739.
  11. Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group. Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. American Heart Journal 2008;156(3):528-536,536.e1-5. PMID: 18760137. PMCID: PMC2701266
  12. Pambianco G, Lombardero M, Bittner V, Forker A, Kennedy F, Krishnaswami A, Mooradian AD, Pop-Busui R, Rana JS, Rodriguez A, Steffes M, Orchard TJ. Control of lipids at baseline in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Preventive Cardiology 2009; 12:9-18. PMID: 19301686. PMCID: PMC2717619.
  13. Schwartz L, Kip KE, Alderman E, Lu J, Bates ER, Srinivas V, Bach RG, Mighton LD, Feit F, King SB III, Frye RL for the BARI 2D Study Group. Baseline coronary angiographic findings in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial (BARI 2D). American Journal of Cardiology 2009;103(5):632-638. PMID: 19231325.
  14. Pop-Busui R, Lu J, Lopes N, Jones TLZ for the BARI 2D Study Group. Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort. Journal of the Peripheral Nervous System 2009;14:1–13. PMID: 19335534. PMCID: PMC2692660.
  15. Schneider DJ, Hardison RM, Lopes N, Sobel BE, Brooks MM and the Pro-Thrombosis Ancillary Study Group. Association between increased platelet p-selectin expression and obesity in patients with type 2 diabetes: A BARI 2D substudy. Diabetes Care 2009;32:944-949. PMID: 19228864. PMCID: PMC2671133.
  16. Kim LJ, King SB III, Kent K, Brooks MM, Kip KE, Abbott JD, Jacobs AK, Rihal C, Hueb WA, Alderman E, Pena Sing IR, Attubato MJ, Feit F for the BARI 2D Study Group. Factors related to the selection of surgical versus percutaneous revascularization in diabetic patients with multivessel coronary artery disease in the BARI 2D trial. Journal of the American College of Cardiology: Cardiovascular Interventions 2009;2:384-392. PMID: 19463459. PMCID: PMC3625397.
  17. The BARI 2D Study Group, Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE. A randomized trial of therapies for type 2 diabetes and coronary artery disease. New England Journal of Medicine 2009; 11;360(24):2503-15. PMID: 19502645. PMCID: PMC2863990.
  18. Pop-Busui R, Lombardero M, Lavis V, Forker A, Green J, Korytkowski M, Sobel BE, Jones TLZ, and the BARI 2D Study Group. Relation of severe coronary artery narrowing to insulin or thiazolidinedione use in patients with type 2 diabetes mellitus (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes Study). American Journal of Cardiology 2009;104(1):52-58. PMID: 19576321. PMCID: PMC2756995.
  19. Chaitman BR, Hardison RM, Adler D, Gebhart S, Grogan M, Ocampo S, Sopko G, Ramires JA, Schneider D, Frye RL, and the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation 2009;120: 2529-2540. PMID: 19920001. PMCID: PMC2830563
  20. Hlatky MA, Boothroyd DB, Melsop KA, Kennedy L, Rihal C, Rogers WJ, Venkitachalam L, Brooks MM, for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group. Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial. Circulation 2009;120:2550-2558. PMID: 19920002. PMCID: PMC3403834.
  21. McBane RD, Hardison RM, Sobel BE, Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen, fibrinogen, and d-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial). American Journal of Cardiology 2010;105(1):17-24. PMID: 20102884. PMID: PMC2814593.
  22. Escobedo J, Rana JS, Lombardero MS, Albert SG, Davis, AM, Kennedy FP, Mooradian AD, Robertson DG, Srinivas VS, Gebhart SSP, and for the BARI 2D Study Group. Association between albuminuria and duration of diabetes and myocardial dysfunction and peripheral arterial disease among patients with stable coronary artery disease in the BARI 2D Study. Mayo Clinic Proceedings 2010;85(1):41-46. PMID: 20042560. PMCID: PMC2800289.
  23. Albu JB, Lu J, Mooradian AD, Krone RJ, Nesto RW, Porter MH, Rana JS, Rogers WJ, Sobel BE, Gottlieb SH and for the BARI 2D Study Group.Relationships of obesity and fat distribution with atherothrombotic risk factors: Baseline results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Obesity (Silver Spring). 2010;18(5):1046-54. PMID: 19875998.
  24. Hlatky MA, Chung S-C, Escobedo J, Hillegass WB, Melsop K, Rogers W, Brooks MM for the BARI 2D Study Group. The effect of obesity on quality of life in patients with diabetes and coronary artery disease. Am Heart J 2010;159:292-300. PMID: 20152229.
  25. Thomas SB, Sansing VV, Davis A, Magee M, Massaro E, Srinivas VS, Helmy T, Desvigne-Nickens P, Brooks MM, and BARI 2D Study Group. Racial differences in the association between self-rated health status and objective clinical measures among participants in the BARI 2D Trial. Am J Public Health 2010;100(suppl 1):S269-76. PMID: 20147671. PMCID: PMC2837445
  26. Rana JS, Hardison RM, Pop-Busui R, Brooks MM, Jones TLZ, Nesto RW, Bourassa MG, and the BARI 2D Investigators. Resting heart rate and metabolic syndrome in patients with diabetes and coronary artery disease in Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Preventive Cardiology 2010;13:112-6. PMID: 20626665.
  27. Wall BM, Hardison RM, Molitch ME, Marroquin OC, McGill JB, August PA; for the BARI 2D Study Group. High prevalence and diversity of kidney dysfunction in patients with type 2 diabetes mellitus and coronary artery disease: The BARI 2D baseline data. Am J Med Sci 2010 Mar 31;339:401-10. PMID: 20375690
  28. Grogan M, Jenkins M, Sansing VV, MacGregor J, Brooks MM, Julien-Williams P, Amendola A, Abbott JD. Health insurance status and control of diabetes and coronary artery disease risk factors on enrollment into the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Diabetes Educ 2010;36(5):774-83. PMID: 20584997.
  29. Brooks MM, Chung SC, Helmy T, Hillegass WB, Escobedo J, Melsop KA, Massaro EM, McBane RD, Hyde P, Hlatky MA; the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group. Health status after treatment for coronary artery disease and type 2 diabetes mellitus in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. Circulation 2010;122:1690-99. PMID: 20937978. PMCID: PMC2964421.
  30. Tamis-Holland JE, Lu J, Bittner V, Magee MF, Lopes N, Adler D, Kip KE, Schwartz L, Groenewoud Y, Jacobs AK, for the BARI 2D Study Group. Sex, clinical symptoms, and angiographic findings in patients with diabetes mellitus and coronary artery disease (from the Bypass Angioplasty Revascularization Investigation [BARI] 2D). American Journal of Cardiology 2011;107(7):980-985. PMID: 21276585.
  31. Singh PP, Abbott JD, Lombardero MS, Sutton-Tyrrell K, Woodhead G, Venjitachalam L, Tsapatsaris NP, Piemonte TC, Lago RM, Rutter MK, Nesto RW, and the BARI 2D Investigators. The prevalence and predictors of an abnormal ankle-brachial index in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Diabetes Care 2011;34(2):464-467. PMC3024368.
  32. Beohar N, Davidson CJ, Massaro E, Srinivas VS, Sansing VV, Zonszein J, Davis AM, Helmy T, Lopes N, Thomas SB, Brooks MM, and the BARI 2D Study Group. The Impact of race/ethnicity on baseline characteristics and the burden of coronary atherosclerosis in the Bypass Angioplasty Revascularization Investigation of Type 2 Diabetes (BARI 2D). American Heart Journal 2011;161:755-63. PMID: 21473976.
  33. Dagenais GR, Lu J, Faxon DP, Kent K, Lago RM, Lezama C, Hueb W, Weiss W, Slater J, Frye RL, for the BARI 2D Trial Research Group. Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease. Circulation2011;123:1492-500. PMID: 21444887.
  34. Chung S-C, Hlatky MA, Stone RA, Rana, JS, Escobedo J, Rogers WJ, Bromberger JT, Kelsey SF, Brooks MM, and the BARI 2D Study Group. Body mass index and health status in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial (BARI 2D). Am Heart J 2011;162:184-192.  PMID: 21742107. PMCID: PMC3141323.
  35. Sobel BE, Hardison RM, Genuth S, Brooks MM, McBane RD, Schneider, DJ, Pratley RE, Huber K, Wolk R, Krishnaswami A, Frye RL, and for the BARI 2D Investigators. Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes. Circulation 2011;124:695-703. PMID: 21768545. PMCID: PMC4220292.
  36. Chung S-C, Hlatky MA, Faxon DP, Ramanathan K, Adler D, Mooradian AD,, Rihal C, Stone RA, Bromberger JT, Kelsey SF, Brooks MM and the BARI 2D Study Group. The effect of age on clinical outcomes and health status in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial (BARI 2D). J Am Coll Cardiol 2011;58(8):810-9. PMID: 21835316. PMC3164969.
  37. Cresci S, Wu J, Province MA, Spertus JA, Steffes M, McGill JB, Alderman EL, Brooks MM, Kelsey SF, Frye RL, Bach RG. Peroxisome proliferator-activated receptor pathway gene polymorphism associated with extent of   in patients with type 2 diabetes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial/clinical perspective. Circulation2011;124(13):1426-34. PMID: 21911782. PMC3629972.
  38. Krishnaswami AR, Hardison R, Nesto RW, Sobel, B. Presentation in patients with angiographically documented coronary artery disease and type ii diabetes mellitus (from the BARI 2D clinical trial). The Am J Cardiol 2012;109(1):36-41. PMID: 21958742.
  39. Schwartz L, Bertolet M, Feit F, Fuentes F, Sako EY, Toosi MS, Davidson CJ, Ikeno F, King SB. Impact of completeness of revascularization on long-term cardiovascular outcomes in patients with type 2 diabetes mellitus: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D). Circ Cardiovasc Interv. 2012;2:166-173. PMID: 22496082.
  40. Shaw LJ, Cerqueira MD, Brooks MM, Althouse AD, Sansing VV, Beller GA, Pop-Busui R, Taillefer R, Chaitman BR, Gibbons RJ, Heo J, Iskandrian AE. Impact of left ventricular function and the extent of ischemia and scar by stress myocardial perfusion imaging on prognosis and therapeutic risk reduction in diabetic patients with coronary artery disease: Results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. J Nucl Cardiol. 2012;19(4):658-69. PMID: 22527794; PMCID: PMC4135719.
  41. Brooks MM, Chaitman BR, Nesto RW, Hardison RM, Feit F, Gersh BJ, Krone RJ, Sako EY, Rogers WJ, Garber AJ, King SB 3rd, Davidson CJ, Ikeno F, Frye RL; BARI 2D Study Group. Clinical and angiographic risk stratification and differential impact on treatment outcomes in the BARI 2D trial. Circulation. 2012;126:2115-24. PMID: 23008442. PMCID: PMC410411.
  42. Abbott JD, Lombardero MS, Barsness GW, Pena-Sing I, Buitrón LV, Singh P, Woodhead G, Tardif JC, Kelsey SF. Ankle-brachial index and cardiovascular outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. American Heart Journal2012;164:585-90. PMCID: PMC3474978.
  43. Bertolet M, Brooks MM, Bittner V. Tree-based identification of subgroups for time-varying covariate survival data. Stat Methods Med Res. 2012;Oct 14. [epub]. PMID: 2307055.
  44. Dagenais GR, Lu J, Faxon DP, Bogaty P, Adler D, Fuentes F, Escobedo J, Krishnaswami A, Slater J, Frye RL; BARI 2D Study Group. Prognostic impact of the presence and absence of angina on mortality and cardiovascular outcomes in patients with type 2 diabetes and stable coronary artery disease: Results from the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial. J Am Coll Cardiol2013;19;61(7):702-11.  PMID: 23410541. PMCID: PMC3701296.
  45. Ismail-Beigi F, Lombardero MS, Escobedo J, Genuth S, Green J, Massaro E, Mooradian AD, Ovalle F, Whitehouse F, Zonszein J; the BARI 2D Study Group. Determinants of successful glycemic control among participants in the BARI 2D Trial: A post-hoc analysis. J Diabetes Complications 2014;28(1):101-9. PMID: 23478173. PMCID: PMC4156749.
  46. Farkouh ME, Boden WE, Bittner V, Muratov V, Hartigan P, Ogdie M, Bertolet M, Mathewkutty S, Teo K, Maron DJ, Sethi SS, Domanski M, Frye RL, Fuster V. Risk factor control for coronary artery disease secondary prevention in large randomized trials. J Am Coll Cardiol 2013 Apr 16;61(15):1607-15. PMID: 23500281.
  47. Tamis-Holland JE, Lu J, Korytkowski M, Magee M, Rogers WJ, Lopes N, Mighton L, Jacobs AK; BARI 2D Study Group. Sex differences in presentation and outcome among patients with type 2 diabetes and coronary artery disease treated with contemporary medical therapy with or without prompt revascularization: A report from the BARI 2D trial (Bypass Angioplasty Revascularization Investigation 2 Diabetes). J Am Coll Cardiol 2013 Apr 30;61(17):1767-76. PMID: 23500245.
  48. Althouse AD, Abbott JD, Sutton-Tyrrell K, Forker AD, Lombardero MS, Buitrón LV, Pena-Sing I, Tardif JC, Mori Brooks M; for the BARI 2D Study Group. Favorable Effects of Insulin Sensitizers Pertinent to Peripheral Arterial Disease in Type 2 Diabetes: Results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Diabetes Care 2013 Oct:36(10):3269-75. PMID: 23735723. PMCID: PMC3781574.
  49. Pop-Busui R, Lu J, Brooks MM, Albert S, Althouse AD, Escobedo J, Green J, Palumbo P, Perkins BA, Whitehouse F, Jones TL; for the BARI 2D Study Group. Impact of Glycemic Control Strategies on the Progression of Diabetic Peripheral Neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. Diabetes Care2013 Oct;36(10):3208-15. PMID: 23757426. PMCID: PMC3781573.
  50. Bach RG, Brooks MM, Lombardero M, Genuth S, Donner TW, Garber AJ, Kennedy L, Monrad ES, Pop-Busui R, Kelsey SF, Frye RL, for the BARI 2D Investigators. Rosiglitazone and Outcomes for Patients with Diabetes and Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation 2013; Aug 128(8):785-94. PMCID: PMC3816149.
  51. Beohar N, Sansing VV, Davis AM, Srinivas VS, Helmy T, Althouse AD, Thomas SB, Brooks MM, and the BARI 2d Study Group. Race/ethnic disparities in risk factor control and survival in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Am J Cardiol 2013 Nov 112(9):1298-1305. PMCID: PMC3837550.
  52. Shah B, Srinivas VS, Lu J, Brooks MM, Bates ER, Nedelijkovic ZS, Escobedo J, Das GS, Lopez JJ, Feit F. Change in enrollment patterns, patient selection, and clinical outcomes with the availability of drug-eluting stents in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. Am Heart J. 2013;166(3):519-26. PMID: 24016502. PMCID: PMC3867930.
  53. August P, Hardison RM, Hage FG, Marroquin OC, McGill JB, Rosenberg Y, Steffes M, Wall BM, Molitch M, for the BARI2D Study Group. Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D Study. Clin J Am Soc Nephrol 2014; Jan;9(1):64-71. PMID: 24178969. PMCID: PMC3878713.
  54. Althouse AD, Abbott JD, Forker AD, Bertolet M, Barinas-Mitchell E, Thurston RC, Mulukutla S, Aboyans V, Brooks MM, for the BARI 2D Study Group. Risk Factors for Incident Peripheral Arterial Disease in Type 2 Diabetes: Results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Diabetes Care2014 May;37(5):1346-52. PMCID: PMC3994929.
  55. Stergiopoulos K, Boden WE, Hartigan P, Mobius-Winkler S, Hambrecht R, Hueb W, Hardison RM, Abbott JD, Brown DL. Percutaneous Coronary Intervention Outcomes in Patients with Stable Obstructive Coronary Artery Disease and Myocardial Ischemia: A Collaborative Meta-analysis of Contemporary Randomized Clinical Trials. JAMA Intern Med. 2013 Dec: 174(2):232-240. PMID: 24296791. PMCID: Journal in process.
  56. Wolk R, Bertolet M, Brooks MM, Pratley RE, Sobel BE, Frye RL, Singh Prachi, Calvin AD, Rutler MK, Mooradian AD, Somers VK and the BARI 2D Study Group. Differential effects of insulin sensitization and insulin provision treatment strategies on concentrations of circulating adipokines in patients with diabetes and coronary artery disease in the BARI 2D trial. Eur J Prev Cardiol.2014 Jul 29. pii: 2047487314544046. [Epub ahead of print.] PMID: 25073857. PMCID: PMC4385003.
  57. Sako EY, Brooks MM, Hardison RM, Schaff H, Frye RL. Coronary artery bypass in patients with type 2 diabetes: Experience from the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. J Thorac Cardiovasc Surg. 2014 Oct;148(4):1268-72. doi: 10.1016/j.jtcvs.2013.11.038. PMID: 24507404. PMCID: PMC4079766.
  58. Krone RJ, Althouse AD, Tamis-Holland J, Venkitachalam L, Campos A, Forker A, Jacobs AK, Ocampos S, Steiner G, Fuentes F, Sing IRP, Brooks MM, for the BARI 2D Study Group. Appropriate Revascularization in Stable Angina, Lessons from the BARI 2D Trial. Canadian Journal of Cardiology 2014;30(12):1595-1601. PMID: 2547546. PMCID: PMC42665566.
  59. MaGee MF, Tamis-Holland JE, Lu J, Bittner VA, Brooks MM, Lopes N, Jacobs AK, and BARI 2D Study Group. Sex, prescribing practices and guideline recommended, blood pressure, and LDL cholesterol targets at baseline in the BARI 2D trial. International Journal of Endocrinology. 2015; Volume 2015, Article ID 610239, 11 pages. PMID:25873955.PMCID: PMC4383496.
  60. Zonszein J, Lombardero M, Ismail-Beigi F, Palumbo P, Foucher S, Groenewoud Y, Cushing G, Wajchenberg B, Genuth S, and BARI 2D Study Group. Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes: A Post Hoc Analysis of the BARI 2D. Journal of Diabetes Research. 2015; Volume 2015, Article ID 129891, 12 pages. PMID:26106623. PMCID: PMC4461783.
  61. Singh A, Schaff HV, Brooks MM, Hlatky MA, Wisniewski SR, Frye RL, Sako EY, the BARI 2D Study Group. On-pump versus off-pump coronary artery bypass graft surgery among patients with type 2 diabetes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. Eur J Cardiothorac Surg. 2016 Feb;49(2):406-16.. PMID: 25968885. PMCID: PMC4711702.
  62. Bittner V, Bertolet M, Barraza R, Farkouh M, Goldberg S, Ramanathan K, Redmon JB, Sperling L, Rutter M; BARI 2D Study Group. Comprehensive Cardiovascular Risk Factor Control Improves Survival: The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Journal of the American College of Cardiology. 2015;66(7):765-73. PMID: 26271057. PMCID: PMC4550809.
  63. Everett B, Brooks MM, Vlachos HE, Chaitman B, Frye RL, Bhatt DL; BARI 2D Study Group. Troponin and cardiac events in stable ischemic heart disease and diabetes. N Engl J Med. 2015 Aug 13;373(7):610-20. doi: 10.1056/NEJMoa1415921. PMID: 26267622. PMCID: PMC4627639.
  64. Wolk R, Bertolet M, Singh P, Brooks MM, Pratley RE, Frye RL, Mooradian AD, Rutter MK, Calvin AD, Chaitman BR, Somers VK; BARI 2D Study Group. Prognostic Value of Adipokines in Predicting Cardiovascular Outcome: Explaining the Obesity Paradox. Mayo Clin Proc. 2016 Jul;91(7):858-66. PMID: 27289411. PMCID: PMC4935584.
  65. Mancini GB, Farkouh ME, Brooks MM, Chaitman BR, Boden WE, Vlachos H, Hartigan PM, Siami FS, Sidhu MS, Bittner V, Frye R, Fuster V. Medical Treatment and Revascularization Options in Patients With Type 2 Diabetes and Coronary Disease. J Am Coll Cardiol. 2016 Sep 6;68(10):985-95. doi: 10.1016/j.jacc.2016.06.021. PMID: 27585501. PMCID: PMC Journal – In Process.
  66. Everett BM, Brooks MM, Vlachos HE, Chaitman BR, Frye RL, Bhatt DL; BARI 2D Study Group. Sex Differences in Cardiac Troponin and the Risk of Death or Major Cardiovascular Events. J Am Coll Cardiol. 2016 Aug 30;68(9):978-80. doi: 10.1016/j.jacc.2016.06.013. PMID: 27561773. PMCID: PMC Journal – In Process.
  67. Ikeno F, Brooks MM, Nakagawa K, Kim MK, Kaneda H, Mitsutake Y, Vlachos HA, Schwartz L, Frye RL, Kelsey SF, Waseda K, Hlatky MA, and the BARI- 2D Study Group. SYNTAX Score and Long-Term Outcomes, The BARI-2D Trial. Journal of the American College of Cardiology, Vol. 69, No. 4, 2017. http://dx.doi.org/10.1016/j.jacc.2016.10.067